^
Association details:
| Biomarker: | RAC1 P29S |
|---|---|
| Cancer: | Melanoma |
| Drug: | dinaciclib (MK-7965) (CDK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints
Published date:
07/19/2023
Excerpt:
In vitro, CDK9 inhibition impeded the proliferation of in RAC1P29S-mutant melanoma cells...In vivo, combining CDK9 inhibition with anti-PD-1 immune checkpoint blockade significantly inhibited tumor growth only in melanomas that expressed the RAC1P29S mutation.
DOI:
https://doi.org/10.21203/rs.3.rs-3160616/v1
